Additional file 1: of A retrospective cohort study of body mass index and survival in HIV infected patients with and without TB co-infection

Multilingual abstracts in the five official working languages of the United Nations. (PDF 443 kb

Additional file 1: of Mortality and treatment response amongst HIV-infected patients 50 years and older accessing antiretroviral services in South Africa

Figure S1. Flow diagram of cumulative participant attrition over 6 years following enrolment into the CAPRISA Acquired immunodeficiency syndrome (AIDS) treatment program (CAT) with HIV infection on antiretroviral treatment (ART) from June 2004 to December 2012. Figure S2. CD4+ count at ART initiation at different years of enrolment reflecting time dependent bias of increasing CD4+ count thresholds at ART initiation. Figure S3. Kaplan-Meier estimates of cumulative probability of death during the first 6 months for patients exposed to ART according to age groups (log rank p = 0.90). (DOCX 236 kb

Proportion of males testing HIV positive in pre-VMMC HCT by age group.

<p>Proportion of males testing HIV positive in pre-VMMC HCT by age group.</p

VMMCs performed by the CAPRISA VMMC program between March 2011 and February 2013.

<p>VMMCs performed by the CAPRISA clinic per month shown. No recruitment was undertaken in schools in November and December at the request of school officials to avoid disruption to examinations; recruitment was also not undertaken in the school holidays in January. Phase 1 of demand creation (community consultation) began in June 2010 and continued until April 2011. Phase 2 of demand creation (in-school information dissemination) was initiated from May 2011 to the end of February 2012. Phase 3 of demand creation (peer recruitment) began in March 2012 and continued until the February 2013.</p

Adverse Effects March 2012-February 2013.

<p>Post-operative adverse effects for the second year of the VMMC pilot are shown ranked by grade. No intra-operative adverse effects were recorded.</p

Analysis of factors associated with mortality.

<p>Analysis of factors associated with mortality.</p

Mortality rates for men and women stratified by baseline CD4+ cell count and age.

<p>Mortality rates for men and women stratified by baseline CD4+ cell count and age.</p

Mean CD4+ cell count change from baseline over time.

<p>Mean CD4+ cell count change from baseline over time.</p

Analysis of factors associated with mortality.

<p>Analysis of factors associated with mortality.</p

Baseline and follow-up characteristics of men and women initiated on ART.

<p>Baseline and follow-up characteristics of men and women initiated on ART.</p